Talphera, Inc. (TLPH)
USD 0.51
(4.89%)
USD 0.51
(4.89%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 11.99 Million USD | -13.82% |
| 2022 | 20.35 Million USD | -41.9% |
| 2021 | 35.03 Million USD | -13.18% |
| 2020 | 40.34 Million USD | -18.8% |
| 2019 | 49.68 Million USD | 46.56% |
| 2018 | 33.9 Million USD | -5.87% |
| 2017 | 36.01 Million USD | -2.65% |
| 2016 | 36.99 Million USD | 177.71% |
| 2015 | 13.32 Million USD | 16.76% |
| 2014 | 11.41 Million USD | -54.63% |
| 2013 | 25.15 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.23 Million USD | -7.16% |
| 2024 Q2 | 4.27 Million USD | 0.78% |
| 2023 Q2 | 4.22 Million USD | -20.76% |
| 2023 Q1 | 5.32 Million USD | -26.77% |
| 2023 Q3 | 3.42 Million USD | -18.85% |
| 2023 Q4 | 4.56 Million USD | 33.22% |
| 2023 FY | 17.54 Million USD | -13.82% |
| 2022 Q2 | 8.36 Million USD | -3.32% |
| 2022 Q1 | 8.65 Million USD | 24.63% |
| 2022 FY | 20.35 Million USD | -41.9% |
| 2022 Q4 | 7.27 Million USD | 10.75% |
| 2022 Q3 | 6.57 Million USD | -21.47% |
| 2021 Q2 | 9.41 Million USD | 24.26% |
| 2021 Q1 | 7.57 Million USD | 5.35% |
| 2021 FY | 35.03 Million USD | -13.18% |
| 2021 Q4 | 6.94 Million USD | -29.26% |
| 2021 Q3 | 9.81 Million USD | 4.21% |
| 2020 Q1 | 13.62 Million USD | 3.0% |
| 2020 FY | 40.34 Million USD | -18.8% |
| 2020 Q4 | 7.19 Million USD | -4.25% |
| 2020 Q3 | 7.51 Million USD | 1.25% |
| 2020 Q2 | 7.42 Million USD | -45.52% |
| 2019 Q1 | 9.95 Million USD | 29.08% |
| 2019 Q2 | 11.23 Million USD | 12.84% |
| 2019 FY | 49.68 Million USD | 46.56% |
| 2019 Q3 | 10.93 Million USD | -2.63% |
| 2019 Q4 | 13.22 Million USD | 20.91% |
| 2018 Q4 | 7.71 Million USD | 49.26% |
| 2018 Q1 | 3.96 Million USD | 21.26% |
| 2018 Q2 | 3.92 Million USD | -1.01% |
| 2018 FY | 33.9 Million USD | -5.87% |
| 2018 Q3 | 5.16 Million USD | 31.65% |
| 2017 Q1 | 4.33 Million USD | 24.46% |
| 2017 Q3 | 4.96 Million USD | 29.47% |
| 2017 Q4 | 3.26 Million USD | -34.16% |
| 2017 Q2 | 3.83 Million USD | -11.53% |
| 2017 FY | 36.01 Million USD | -2.65% |
| 2016 Q2 | 3.39 Million USD | -0.12% |
| 2016 Q4 | 3.48 Million USD | -22.69% |
| 2016 Q3 | 4.5 Million USD | 32.58% |
| 2016 Q1 | 3.4 Million USD | -18.44% |
| 2016 FY | 36.99 Million USD | 177.71% |
| 2015 FY | 13.32 Million USD | 16.76% |
| 2015 Q1 | 3.11 Million USD | -47.58% |
| 2015 Q4 | 4.17 Million USD | 30.38% |
| 2015 Q2 | 2.74 Million USD | -11.75% |
| 2015 Q3 | 3.19 Million USD | 16.37% |
| 2014 Q3 | 1.9 Million USD | -32.7% |
| 2014 Q4 | 5.94 Million USD | 211.75% |
| 2014 Q2 | 2.83 Million USD | -38.04% |
| 2014 FY | 11.41 Million USD | -54.63% |
| 2014 Q1 | 4.57 Million USD | -7.38% |
| 2013 FY | 25.15 Million USD | 0.0% |
| 2013 Q1 | 3.94 Million USD | 0.0% |
| 2013 Q2 | 11.34 Million USD | 187.46% |
| 2013 Q3 | 4.7 Million USD | -58.54% |
| 2013 Q4 | 4.93 Million USD | 4.93% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -45.331% |
| Alpha Teknova, Inc. | 45.85 Million USD | 73.846% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 93.88% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 73.26% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 92.466% |
| Cosmos Health Inc. | 26.18 Million USD | 54.188% |
| Journey Medical Corporation | 54.59 Million USD | 78.031% |
| Embecta Corp. | 528.4 Million USD | 97.73% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 95.589% |
| Dynavax Technologies Corporation | 219.14 Million USD | 94.527% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 97.967% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 96.325% |
| PainReform Ltd. | 9.58 Million USD | -25.146% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 8.613% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 8.613% |
| SCYNEXIS, Inc. | 51.84 Million USD | 76.867% |
| Safety Shot Inc | 12.1 Million USD | 0.955% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -290.787% |
| Procaps Group, S.A. | 199.47 Million USD | 93.987% |
| Theratechnologies Inc. | 72.75 Million USD | 83.515% |
| Harrow Health, Inc. | 89.97 Million USD | 86.669% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -26.974% |
| Biofrontera Inc. | 39.95 Million USD | 69.984% |
| DURECT Corporation | 43.71 Million USD | 72.563% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.733% |
| Cronos Group Inc. | 96.7 Million USD | 87.598% |
| OptiNose, Inc. | 85.1 Million USD | 85.906% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 94.833% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 69.366% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 225.447% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 96.182% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -23.258% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 72.133% |
| Radius Health, Inc. | 265.92 Million USD | 95.49% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 13.35% |
| ProPhase Labs, Inc. | 37.85 Million USD | 68.313% |
| Phibro Animal Health Corporation | 260.29 Million USD | 95.392% |
| Procaps Group S.A. | 187.24 Million USD | 93.594% |
| Alvotech | 285.43 Million USD | 95.798% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -22.076% |
| Viatris Inc. | 5.96 Billion USD | 99.799% |
| Rockwell Medical, Inc. | 15.37 Million USD | 21.985% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 79.957% |
| SIGA Technologies, Inc. | 22.04 Million USD | 45.588% |
| Tilray Brands, Inc. | 251.35 Million USD | 95.228% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 75.541% |
| Shineco, Inc. | 17.94 Million USD | 33.174% |
| PetIQ, Inc. | 192.72 Million USD | 93.777% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -200.516% |
| Incannex Healthcare Limited | 30.05 Million USD | 60.091% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.249% |
| Alimera Sciences, Inc. | 62.64 Million USD | 80.853% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1473.0% |
| Assertio Holdings, Inc. | 368.58 Million USD | 96.746% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -103.787% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 32.65% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 43.342% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 43.0% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 92.729% |
| Hempacco Co., Inc. | 7.59 Million USD | -57.89% |
| Alvotech | 285.43 Million USD | 95.798% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 91.476% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 96.522% |
| Currenc Group, Inc. | 24 Million USD | 50.029% |
| Kamada Ltd. | 45.42 Million USD | 73.597% |
| Indivior PLC | 911 Million USD | 98.683% |
| Evoke Pharma, Inc. | 12.4 Million USD | 3.349% |
| Flora Growth Corp. | 10.57 Million USD | -13.376% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 43.0% |
| Evolus, Inc. | 189.75 Million USD | 93.679% |
| HUTCHMED (China) Limited | 436.23 Million USD | 97.251% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 92.218% |
| Akanda Corp. | 3.48 Million USD | -244.308% |